GSK expects to have five new products on market by end of decade
GlaxoSmithKline (GSK) expects to launch up to five major new compounds from 2007 - 2010 in cancer prevention, treatment and supportive care across a broad range of cancer types, it told investors and analysts at a meeting this week.
GlaxoSmithKline (GSK) expects to launch up to five major new compounds from 2007 - 2010 in cancer prevention, treatment and supportive care across a broad range of cancer types, it told investors and analysts at a meeting this week.
The multinational presented an overview on its expanding oncology portfolio, with clinical updates on several important new medicines: including Cervarix, for prevention of cervical cancer; Pazopanib, for renal cell carcinoma; Promacta, for thrombocytopenia (initially ITP); Rezonic, for emesis; Ofatumumab (HuMax-CD20 ), for NHL/CL; and Tykerb, a new oral treatment for breast cancer, off to a strong start in USA with approximately 3,000 patients treated since launch in March.
Commenting on the seminar, Moncef Slaoui, chairman of r&d at GSK said: 'Over the next three years, GSK will make a difference to millions of patients facing cancer, with up to five new products expected to be launched in this period. Today demonstrates the significant progress we have made to expand and develop our oncology portfolio.
'We are actively developing late-stage medicines in over 12 different cancer types, from pioneering treatments such as Tykerb to vaccines that can treat as well as prevent cancer. Moving deeper into the pipeline we believe that this productivity in oncology can be sustained as we have a significant number of promising new compounds in early-stage discovery.'